Clinical Trial: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07375524) titled 'A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome' on Jan. 21.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjogren's syndrome.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Primary Sjogren Syndrome

Intervention: DRUG: ESG206

ESG206 Low Dose administered by intravenous infusion

DRUG: ESG206

ESG206 High Dose administered by intravenous infusion

DRUG: Placebo

Placebo administered by intrav...